文献速递免疫规划传染病防控与疫情报告

日本儿童接种BNT162b2疫苗后的不良事件研究

Adverse events post-BNT162b2 vaccination in Japanese children.
PubMed 文献 · Vaccine · 2025-12-30

本研究纳入1016名6月龄至11岁日本儿童,通过在线表单记录接种BNT162b2疫苗后7天内的不良事件。结果显示第1、2、3剂后发热(≥37.5°C)发生率分别为6.2%、14.1%和18.0%,未观察到心肌炎、过敏性休克或惊厥等严重不良事件。高龄、女性、较高剂量、既往接种史、特定病史及父母不良事件史与不良事件风险增加相关。

要点

  • 日本儿童接种BNT162b2疫苗后发热发生率随剂次增加,第3剂达18.0%。
  • 未观察到心肌炎、过敏性休克或惊厥等严重不良事件。
  • 高龄、女性、较高剂量、既往接种史、特定病史及父母不良事件史与不良事件风险增加相关。

核心结论

  • 日本儿童接种BNT162b2疫苗是安全的,不良事件发生率总体较低。

研究设计与样本

  • 前瞻性观察研究,纳入12家合作机构中6月龄至11岁接种BNT162b2疫苗的儿童,共分析1016名儿童(第1、2、3剂分别465、318、233名)。
  • 通过在线表单记录接种后7天内的不良事件,不良事件定义为接种后任何不良医学事件,不一定是疫苗所致。

主要发现

  • 第1、2、3剂后发热(≥37.5°C)发生率分别为6.2%、14.1%、18.0%。
  • 未观察到心肌炎、过敏性休克或惊厥等严重不良事件。
  • 高龄、女性、较高BNT162b2剂量、既往接种史、病史(过敏性休克、免疫性血小板减少症、过敏性疾病、癫痫)及父母不良事件史与不良事件风险增加相关。

临床怎么用

  • 为日本儿童接种BNT162b2疫苗的安全性提供数据,可帮助提升公众信心和疫苗接种率。
  • 接种后应关注发热等不良事件,尤其在高龄、女性、较高剂量、有特定病史或父母有不良事件史的儿童中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: BNT162b2 vaccination rates are low in Japanese children owing to concerns regarding adverse events (AEs). There are few reports indicating AE incidence post-vaccination in Japanese children, and the risk factors for AEs remain unclear. We aimed to elucidate AE incidence and risk factors post-BNT162b2 vaccination in Japanese children. METHODS: Children aged 6 months-11 years who received the BNT162b2 vaccine at 12 collaborating institutions were targeted. An AE was defined as any untoward medical occurrence post-vaccination, not necessarily caused by the vaccination. AEs at 7 days post-BNT162b2 vaccination were recorded and reported via an online form. RESULTS: Data of 1016 Japanese children were analyzed (465, 318, and 233 children had vaccination for dose 1, 2, and 3, respectively). The incidence of fever (≥37.5 °C) post doses 1, 2, and 3 was 6.2 %, 14.1 %, and 18.0 %, respectively. No severe AEs, such as myocarditis, anaphylaxis, or seizures were observed. Older age, female sex, higher BNT162b2 dose, previous vaccination, medical history (anaphylaxis, immune thrombocytopenia, allergic diseases, and epilepsy), and AEs in parents were associated with an increased risk of AEs. CONCLUSIONS: BNT162b2 vaccination in Japanese children was safe. The overall low AE rates and increased knowledge of the patterns and factors associated with AEs may enhance public confidence in vaccination and promote greater uptake of coronavirus disease (COVID-19) vaccination in Japanese children, thus enhancing COVID-19 control.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Okabe H, Hashimoto K, Asano Y, et al. Adverse events post-BNT162b2 vaccination in Japanese children. Vaccine. 2025. PMID: 41475155. doi:10.1016/j.vaccine.2025.128167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。